Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20686120 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Hoang B, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-8 20686120
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T308-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase slight increase
rapamycin IGF-1 no effect upon treatment-induced increase
PP242 IGF-1 no effect upon treatment-induced increase

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 augment treatment-induced increase
PP242 IGF-1 inhibit treatment-induced increase
rapamycin no change compared to control
rictor (human) no change compared to control shRNA no change
IL-6 increase in OPM2 and MM1S MM cells, not in U266 and 8226 MM cells
PTEN (human) decrease
NRas (human) increase
KRas (human) decrease
PP242 decrease MM patient cells

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP242 increase

S2481-p - mTOR (human) ▲
Orthologous residues
mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 no effect upon treatment-induced increase
PP242 IGF-1 inhibit treatment-induced increase
PP242 decrease MM patient cells

S330-p - NDRG1 (human) ▲
Orthologous residues
NDRG1 (human): S330‑p, NDRG1 (mouse): S330‑p, NDRG1 (rat): S330‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 no effect upon treatment-induced increase
PP242 IGF-1 no effect upon treatment-induced increase
rictor (human) increase shRNA decreases

T412-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  multiple myeloma
 Relevant cell lines - cell types - tissues:  MM (B lymphocyte), OPM-2 (B lymphocyte), RPMI-8226, U266 (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 inhibit treatment-induced increase
PP242 IGF-1 inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.